5 results on '"You Hua Xie"'
Search Results
2. Luteolin-7-O-Glucoside Present in Lettuce Extracts Inhibits Hepatitis B Surface Antigen Production and Viral Replication by Human Hepatoma Cells in Vitro
- Author
-
Xiao-Xian Cui, Xiao Yang, Hui-Jing Wang, Xing-Yu Rong, Sha Jing, You-Hua Xie, Dan-Feng Huang, and Chao Zhao
- Subjects
hepatitis B virus ,hepatitis B surface antigen ,luteolin-7-O-glucoside ,reactive oxygen species ,mitochondrial membrane potential ,Microbiology ,QR1-502 - Abstract
Hepatitis B virus (HBV) infection is endemic in Asia and chronic hepatitis B (CHB) is a major public health issue worldwide. Current treatment strategies for CHB are not satisfactory as they induce a low rate of hepatitis B surface antigen (HBsAg) loss. Extracts were prepared from lettuce hydroponically cultivated in solutions containing glycine or nitrate as nitrogen sources. The lettuce extracts exerted potent anti-HBV effects in HepG2 cell lines in vitro, including significant HBsAg inhibition, HBV replication and transcription inhibition, without exerting cytotoxic effects. When used in combination interferon-alpha 2b (IFNα-2b) or lamivudine (3TC), the lettuce extracts synergistically inhibited HBsAg expression and HBV replication. By using differential metabolomics analysis, Luteolin-7-O-glucoside was identified and confirmed as a functional component of the lettuce extracts and exhibited similar anti-HBV activity as the lettuce extracts in vitro. The inhibition rate on HBsAg was up to 77.4%. Moreover, both the lettuce extracts and luteolin-7-O-glucoside functioned as organic antioxidants and, significantly attenuated HBV-induced intracellular reactive oxygen species (ROS) accumulation. Luteolin-7-O-glucoside also normalized ROS-induced mitochondrial membrane potential damage, which suggests luteolin-7-O-glucoside inhibits HBsAg and HBV replication via a mechanism involving the mitochondria. Our findings suggest luteolin-7-O-glucoside may have potential value for clinical application in CHB and may enhance HBsAg and HBV clearance when used as a combination therapy.
- Published
- 2017
- Full Text
- View/download PDF
3. Characterization of the 3a Protein of SARS-associated Coronavirus in Infected Vero E6 Cells and SARS Patients☆
- Author
-
Bin Ying Si, Mu De Shi, Bing Sun, Xiao Dong Wu, Cui E. Wang, Lei Zhang, En Xie, Yuan Wang, Lv Shi, Xiao-Sheng Jiang, Yong Yong Ji, Gang Pei, Jin Wang, Song Hua Chen, Xiaoyi Wang, Hu Zhou, Ying Lin, Lei Xiong, Rong Zeng, Yan Jin, Jia Rui Wu, Yu Chuan Li, Shi Fang Shan, Man Rong Jiang, Hong Qiang Ruan, Ruifu Yang, Er Hei Dai, Jiang Ping Zuo, Zhi Qin Jiang, Hongxia Wang, Xi Zhang, You Hua Xie, Ju Tian Cao, and Yong Hua Gan
- Subjects
Proteomics ,Sequence analysis ,proteome ,coronavirus ,Peptide ,Biology ,medicine.disease_cause ,spike protein ,Article ,Viroporin Proteins ,CoV, corona virus ,Viral Proteins ,Viral Envelope Proteins ,Structural Biology ,Sequence Analysis, Protein ,Chlorocebus aethiops ,medicine ,Viral structural protein ,Animals ,Humans ,SARS, severe acute respiratory syndrome ,Disulfides ,skin and connective tissue diseases ,Molecular Biology ,Vero Cells ,Phylogeny ,Coronavirus ,chemistry.chemical_classification ,SARS ,Membrane Glycoproteins ,fungi ,Virology ,Molecular biology ,body regions ,chemistry ,Severe acute respiratory syndrome-related coronavirus ,Proteome ,Spike Glycoprotein, Coronavirus ,Vero cell ,Function (biology) ,3a protein - Abstract
Proteomics was used to identify a protein encoded by ORF 3a in a SARS-associated coronavirus (SARS-CoV). Immuno-blotting revealed that interchain disulfide bonds might be formed between this protein and the spike protein. ELISA indicated that sera from SARS patients have significant positive reactions with synthesized peptides derived from the 3a protein. These results are concordant with that of a spike protein-derived peptide. A tendency exists for co-mutation between the 3a protein and the spike protein of SARS-CoV isolates, suggesting that the function of the 3a protein correlates with the spike protein. Taken together, the 3a protein might be tightly correlated to the spike protein in the SARS-CoV functions. The 3a protein may serve as a new clinical marker or drug target for SARS treatment.
- Published
- 2004
4. Synthetic peptides derived from SARS coronavirus S protein with diagnostic and therapeutic potential
- Author
-
Lin Chen Yan, Hongxia Wang, Lin Tian, Xiao Dong Wu, Sheng Yang, Bing Sun, Weihong Jiang, Chao Bian, Mu De Shi, Jin Wang, Ruifu Yang, Guo Mei Lin, Jia Rui Wu, Yong Yong Ji, Gang Pei, Ying Lin, Xueliang Zhu, Tie Liu Shi, Yixue Li, Wei Lu, You Hua Xie, and You Yu He
- Subjects
Antigenicity ,viruses ,Blotting, Western ,Molecular Sequence Data ,Biophysics ,Peptide ,Biology ,Spike protein ,Biochemistry ,Article ,Syncytia formation and disease prevention ,Viral Proteins ,Protein sequencing ,Structural Biology ,In vivo ,Genetics ,Viral structural protein ,Humans ,Amino Acid Sequence ,Molecular Biology ,Peptide sequence ,SARS-CoV, severe acute respiratory syndrome-associated coronavirus ,chemistry.chemical_classification ,Computational Biology ,virus diseases ,Severe acute respiratory syndrome coronavirus ,Cell Biology ,Virology ,In vitro ,Synthetic peptide ,Severe acute respiratory syndrome-related coronavirus ,chemistry ,biology.protein ,Antibody ,Peptides ,Abs, antibodies - Abstract
The spike (S) protein of severe acute respiratory syndrome coronavirus (SARS-CoV) is an important viral structural protein. Based on bioinformatics analysis, 10 antigenic peptides derived from the S protein sequence were selected and synthesized. The antigenicity and immunoreactivity of all the peptides were tested in vivo and in vitro. Four peptides (P6, P8, P9 and P10) which contain B cell epitopes of the S protein were identified, and P8 peptide was confirmed in vivo to have a potential in serological diagnosis. By using a syncytia formation model, we tested the neutralization ability of all 10 peptides and their corresponding antibodies. It is interesting to find that P8 and P9 peptides inhibited syncytia formation, suggesting that the P8 and P9 spanning regions may provide a good target for anti-SARS-CoV drug design. Our data suggest that we have identified peptides derived from the S protein of SARS-CoV, which are useful for SARS treatment and diagnosis.
- Full Text
- View/download PDF
5. Identification and Characterization of Peptides That Interact with Hepatitis B Virus via the Putative Receptor Binding Site.
- Author
-
Qiang Deng, Jian-wei Zhai, Michel, Marie-Louise, Jun Zhang, Jun Qin, Yu-ying Kong, Xin-xin Zhang, Budkowska, Agata, Tiollais, Pierre, Yuan Wang, and You-hua Xie
- Subjects
- *
HEPATITIS B virus , *PROTEINS , *AMINO acids , *LIVER cells , *PEPTIDES , *LIPOPROTEINS - Abstract
A direct involvement of the PreS domain of the hepatitis B virus (HBV) large envelope protein, and in particular amino acid residues 21 to 47, in virus attachment to hepatocytes has been suggested by many previous studies. Several PreS-interacting proteins have been identified. However, they share few common sequence motifs, and a bona fide cellular receptor for HBV remains elusive. In this study, we aimed to identify PreS-interacting motifs and to search for novel HBV-interacting proteins and the long-sought receptor. PreS fusion proteins were used as baits to screen a phage display library of random peptides. A group of PreS-binding peptides were obtained. These peptides could bind to amino acids 21 to 47 of PreS1 and shared a linear motif (W1T2X3W4W5) sufficient for binding specifically to PreS and viral particles. Several human proteins with such a motif were identified through BLAST search. Analysis of their biochemical and structural properties suggested that lipoprotein lipase (LPL), a key enzyme in lipoprotein metabolism, might interact with PreS and HBV particles. The interaction of HBV with LPL was demonstrated by in vitro binding, virus capture, and cell attachment assays. These findings suggest that LPL may play a role in the initiation of HBV infection. Identification of peptides and protein ligands corresponding to LPL that bind to the HBV envelope will offer new therapeutic strategies against HBV infection. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.